EYPT EyePoint Pharmaceuticals Inc.

2.19
-0.01  -0%
Previous Close 2.19
Open 2.19
Price To Book 5.6
Market Cap 208392706
Shares 95,374,236
Volume 127,970
Short Ratio
Av. Daily Volume 301,271

NewsSee all news

  1. Edited Transcript of EYPT earnings conference call or presentation 14-Mar-19 12:30pm GMT
  2. EYEPOINT PHARMACEUTICALS INC (EYPT) Q2 2019 Earnings Conference Call Transcript
  3. EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
  4. EyePoint Pharmaceuticals: Fiscal 2Q Earnings Snapshot
  5. EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced October 15, 2018.
YUTIQ
Non-infectious uveitis

Latest News

  1. Edited Transcript of EYPT earnings conference call or presentation 14-Mar-19 12:30pm GMT
  2. EYEPOINT PHARMACEUTICALS INC (EYPT) Q2 2019 Earnings Conference Call Transcript
  3. EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
  4. EyePoint Pharmaceuticals: Fiscal 2Q Earnings Snapshot
  5. EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments
  6. The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie
  7. EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCUTM (dexamethasone intraocular suspension) 9%
  8. EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information
  9. EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility
  10. EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
  11. Earnings Preview: EyePoint Pharmaceuticals (EYPT) Q2 Earnings Expected to Decline
  12. EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors
  13. 4 Pharma Stocks Raising Eyebrows (1/3/19)
  14. EyePoint Pharmaceuticals Provides 2019 Commercial Update
  15. Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options
  16. EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary
  17. EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)  
  18. EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
  19. EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates